Found vs Hims & Hers
Two GLP-1 desks, one scoreboard. We put Found and Hims & Hers head-to-head on the published Brief Score — the same six factors, scored the same way.
Hims & Hers
FDA warning letter, September 2025 — issued to Hims & Hers Health, Inc. dba Hims. See the FDA's warning letter database.
The verdict
Hims & Hers takes this head-to-head.
Hims & Hers scores 85 to 81 on our six-factor Brief Score — Mass-market, app-first weight program with nationwide reach — watch the compounded-supply headlines.
That doesn't make Found a bad call — it's best for readers who want insurance run against their clinical visits and a clinician free to move them between compounded, brand and oral routes. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Found | Hims & Hers | |
|---|---|---|
| Brief Score | 81/100 (B−) | 85/100 (B) |
| Semaglutide | $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); the advertised $99 is the in-network INSURANCE rate and still sits before a ~$30 per-visit copay | $199/mo |
| Tirzepatide | $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); one program price covers both molecules | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Risingprice rising |
Found: Headline unchanged, but our $129 line was wrong: the published floor is $99 and it requires a 3-, 6- or 12-month plan.
Hims & Hers: App-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.